MDedge Dermatology

Key clinical point: Adjuvant supplementation with single-strain probiotic lactobacilli significantly reduced the SCORing Atopic Dermatitis (SCORAD) index in young patients with atopic dermatitis (AD).

Major finding: The single-strain probiotic lactobacilli vs placebo group had a significant reduction in the SCORAD index (mean difference −4.50; P  =  .003).

Study details: Findings are from a meta-analysis of 14 studies involving 1124 patients aged 0-18 years with AD who received single-strain probiotic lactobacilli (n = 574) or placebo (n = 550).

Disclosures: This study was funded by the Slovenian Research Agency. The authors declared no conflicts of interest.

Source: Fijan S et al. Single-strain probiotic lactobacilli for the treatment of atopic dermatitis in children: A systematic review and meta-analysis. Pharmaceutics. 2023;15(4):1256 (Apr 17). Doi: 10.3390/pharmaceutics15041256

Key clinical point: Adjuvant supplementation with single-strain probiotic lactobacilli significantly reduced the SCORing Atopic Dermatitis (SCORAD) index in young patients with atopic dermatitis (AD).

Major finding: The single-strain probiotic lactobacilli vs placebo group had a significant reduction in the SCORAD index (mean difference −4.50; P  =  .003).

Study details: Findings are from a meta-analysis of 14 studies involving 1124 patients aged 0-18 years with AD who received single-strain probiotic lactobacilli (n = 574) or placebo (n = 550).

Disclosures: This study was funded by the Slovenian Research Agency. The authors declared no conflicts of interest.

Source: Fijan S et al. Single-strain probiotic lactobacilli for the treatment of atopic dermatitis in children: A systematic review and meta-analysis. Pharmaceutics. 2023;15(4):1256 (Apr 17). Doi: 10.3390/pharmaceutics15041256

Key clinical point: Adjuvant supplementation with single-strain probiotic lactobacilli significantly reduced the SCORing Atopic Dermatitis (SCORAD) index in young patients with atopic dermatitis (AD).

Major finding: The single-strain probiotic lactobacilli vs placebo group had a significant reduction in the SCORAD index (mean difference −4.50; P  =  .003).

Study details: Findings are from a meta-analysis of 14 studies involving 1124 patients aged 0-18 years with AD who received single-strain probiotic lactobacilli (n = 574) or placebo (n = 550).

Disclosures: This study was funded by the Slovenian Research Agency. The authors declared no conflicts of interest.

Source: Fijan S et al. Single-strain probiotic lactobacilli for the treatment of atopic dermatitis in children: A systematic review and meta-analysis. Pharmaceutics. 2023;15(4):1256 (Apr 17). Doi: 10.3390/pharmaceutics15041256

Key clinical point: A lower alpha diversity in infancy is associated with an increased risk for atopic dermatitis (AD) in children of parents with atopy.

Major finding: Overall, the skin microbiome at birth and 2 months of age was not associated with the subsequent development of AD (P  =  .2). However, a lower alpha diversity at 2 months of age was significantly associated with an increased risk for AD during the first 2 years in children with at least 1 parent (adjusted hazard ratio [aHR] 1.67; P  =  .03) or both parents (aHR 4.44; P  =  .04) with a history of atopy.

Study details: Findings are from a prospective analysis of 300 children born to term, of which 153 had a parental history of atopy.

Disclosures: This study was funded by The Leo Foundation and others. Some authors declared serving as speakers, advisors, or consultants for or receiving research grants or speaker or consulting honoraria from various organizations, including the study funders.

Source: Halling AS et al. Reduced skin microbiome diversity in infancy is associated with increased risk of atopic dermatitis in high-risk children. J Invest Dermatol. 2023 (Apr 19). Doi: 10.1016/j.jid.2023.03.1682

Key clinical point: A lower alpha diversity in infancy is associated with an increased risk for atopic dermatitis (AD) in children of parents with atopy.

Major finding: Overall, the skin microbiome at birth and 2 months of age was not associated with the subsequent development of AD (P  =  .2). However, a lower alpha diversity at 2 months of age was significantly associated with an increased risk for AD during the first 2 years in children with at least 1 parent (adjusted hazard ratio [aHR] 1.67; P  =  .03) or both parents (aHR 4.44; P  =  .04) with a history of atopy.

Study details: Findings are from a prospective analysis of 300 children born to term, of which 153 had a parental history of atopy.

Disclosures: This study was funded by The Leo Foundation and others. Some authors declared serving as speakers, advisors, or consultants for or receiving research grants or speaker or consulting honoraria from various organizations, including the study funders.

Source: Halling AS et al. Reduced skin microbiome diversity in infancy is associated with increased risk of atopic dermatitis in high-risk children. J Invest Dermatol. 2023 (Apr 19). Doi: 10.1016/j.jid.2023.03.1682

Key clinical point: A lower alpha diversity in infancy is associated with an increased risk for atopic dermatitis (AD) in children of parents with atopy.

Major finding: Overall, the skin microbiome at birth and 2 months of age was not associated with the subsequent development of AD (P  =  .2). However, a lower alpha diversity at 2 months of age was significantly associated with an increased risk for AD during the first 2 years in children with at least 1 parent (adjusted hazard ratio [aHR] 1.67; P  =  .03) or both parents (aHR 4.44; P  =  .04) with a history of atopy.

Study details: Findings are from a prospective analysis of 300 children born to term, of which 153 had a parental history of atopy.

Disclosures: This study was funded by The Leo Foundation and others. Some authors declared serving as speakers, advisors, or consultants for or receiving research grants or speaker or consulting honoraria from various organizations, including the study funders.

Source: Halling AS et al. Reduced skin microbiome diversity in infancy is associated with increased risk of atopic dermatitis in high-risk children. J Invest Dermatol. 2023 (Apr 19). Doi: 10.1016/j.jid.2023.03.1682

Key clinical point: Patients with atopic dermatitis (AD) have a 1.28-fold increased risk of developing rheumatoid arthritis (RA) but patients with RA do not have an increased risk of developing AD.

Major finding: Patients with AD had a significantly increased risk of developing RA (odds ratio [OR] 1.28; P < .001). However, the risk of developing AD in patients with RA was not significant (OR 1.10; P  =  .52).

Study details: The data come from a systematic review and meta-analysis of nine studies that investigated the association between AD and RA.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Williams RC et al. The uni-directional association of atopic dermatitis and rheumatoid arthritis: A systematic review and meta‑analysis. Arch Dermatol Res. 2023 (Apr 12). Doi: 10.1007/s00403-023-02619-0

Key clinical point: Patients with atopic dermatitis (AD) have a 1.28-fold increased risk of developing rheumatoid arthritis (RA) but patients with RA do not have an increased risk of developing AD.

Major finding: Patients with AD had a significantly increased risk of developing RA (odds ratio [OR] 1.28; P < .001). However, the risk of developing AD in patients with RA was not significant (OR 1.10; P  =  .52).

Study details: The data come from a systematic review and meta-analysis of nine studies that investigated the association between AD and RA.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Williams RC et al. The uni-directional association of atopic dermatitis and rheumatoid arthritis: A systematic review and meta‑analysis. Arch Dermatol Res. 2023 (Apr 12). Doi: 10.1007/s00403-023-02619-0

Key clinical point: Patients with atopic dermatitis (AD) have a 1.28-fold increased risk of developing rheumatoid arthritis (RA) but patients with RA do not have an increased risk of developing AD.

Major finding: Patients with AD had a significantly increased risk of developing RA (odds ratio [OR] 1.28; P < .001). However, the risk of developing AD in patients with RA was not significant (OR 1.10; P  =  .52).

Study details: The data come from a systematic review and meta-analysis of nine studies that investigated the association between AD and RA.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Williams RC et al. The uni-directional association of atopic dermatitis and rheumatoid arthritis: A systematic review and meta‑analysis. Arch Dermatol Res. 2023 (Apr 12). Doi: 10.1007/s00403-023-02619-0

Key clinical point: Treatment with an emollient plus balm significantly reduced corticosteroid use compared with routine treatment with commercial emollients in patients with mild-to-moderate atopic dermatitis (AD).

Major finding: Until day 28, patients receiving emollient plus balm vs a commercial classical emollient used a significantly lower mean amount of corticosteroid (6.03 vs 9.16 g; P  =  .041), with corticosteroids being used on fewer days (37.5% vs 46.9% of days; P  =  .0256) and fewer times daily (0.55 vs 0.71 applications/day; P  =  .0203).

Study details: This single-center randomized controlled study included 119 patients age ≥3 years with mild-to-moderate AD who were randomly assigned to receive an emollient plus balm combination (n = 58) or a classical emollient (n = 61) for 28 days, both along with topical corticosteroids when necessary and as per prescription.

Disclosures: This study was supported by La Roche-Posay (LRP). A-L Demessant-Flavigny, S Salah, and D Kerob declared being employees of LRP. H Zelenkova reported no conflicts of interest.

Source: Zelenkova H et al. Impact of daily use of emollient ‘plus’ on corticosteroid consumption in patients with atopic dermatitis: An open, randomized controlled study. J Eur Acad Dermatol Venereol. 2023 (Apr 24). Doi: 10.1111/jdv.18947

Key clinical point: Treatment with an emollient plus balm significantly reduced corticosteroid use compared with routine treatment with commercial emollients in patients with mild-to-moderate atopic dermatitis (AD).

Major finding: Until day 28, patients receiving emollient plus balm vs a commercial classical emollient used a significantly lower mean amount of corticosteroid (6.03 vs 9.16 g; P  =  .041), with corticosteroids being used on fewer days (37.5% vs 46.9% of days; P  =  .0256) and fewer times daily (0.55 vs 0.71 applications/day; P  =  .0203).

Study details: This single-center randomized controlled study included 119 patients age ≥3 years with mild-to-moderate AD who were randomly assigned to receive an emollient plus balm combination (n = 58) or a classical emollient (n = 61) for 28 days, both along with topical corticosteroids when necessary and as per prescription.

Disclosures: This study was supported by La Roche-Posay (LRP). A-L Demessant-Flavigny, S Salah, and D Kerob declared being employees of LRP. H Zelenkova reported no conflicts of interest.

Source: Zelenkova H et al. Impact of daily use of emollient ‘plus’ on corticosteroid consumption in patients with atopic dermatitis: An open, randomized controlled study. J Eur Acad Dermatol Venereol. 2023 (Apr 24). Doi: 10.1111/jdv.18947

Key clinical point: Treatment with an emollient plus balm significantly reduced corticosteroid use compared with routine treatment with commercial emollients in patients with mild-to-moderate atopic dermatitis (AD).

Major finding: Until day 28, patients receiving emollient plus balm vs a commercial classical emollient used a significantly lower mean amount of corticosteroid (6.03 vs 9.16 g; P  =  .041), with corticosteroids being used on fewer days (37.5% vs 46.9% of days; P  =  .0256) and fewer times daily (0.55 vs 0.71 applications/day; P  =  .0203).

Study details: This single-center randomized controlled study included 119 patients age ≥3 years with mild-to-moderate AD who were randomly assigned to receive an emollient plus balm combination (n = 58) or a classical emollient (n = 61) for 28 days, both along with topical corticosteroids when necessary and as per prescription.

Disclosures: This study was supported by La Roche-Posay (LRP). A-L Demessant-Flavigny, S Salah, and D Kerob declared being employees of LRP. H Zelenkova reported no conflicts of interest.

Source: Zelenkova H et al. Impact of daily use of emollient ‘plus’ on corticosteroid consumption in patients with atopic dermatitis: An open, randomized controlled study. J Eur Acad Dermatol Venereol. 2023 (Apr 24). Doi: 10.1111/jdv.18947

Key clinical point: Tralokinumab demonstrated promising efficacy and an acceptable safety profile in a real-world cohort of patients with a long history of moderate-to-severe atopic dermatitis (AD) and multiple treatment failures.

Major finding: At week 16, the mean Eczema Area and Severity Index (EASI), SCORing AD, and peak pruritus numerical rating scale scores improved by 70.4%, 64.1%, and 57.1%, respectively (all P < .0001), and 57.6% of patients achieved a ≥75% improvement in EASI scores. The safety profile was acceptable.

Study details: Findings are from a multicenter retrospective study including 85 adult patients with moderate-to-severe AD who had unsuccessfully used prior therapy with systemics, biologics, or a Janus kinase inhibitor (n = 27) or were naive to advanced therapy (n = 58) and received tralokinumab.

Disclosures: This study did not receive any funding. Some authors declared serving as investigators, speakers, or consultants for or receiving lecture, speaking, or consulting fees from various sources.

Source: Pereyra-Rodriguez JJ et al. Treatment of severe atopic dermatitis with tralokinumab in real clinical practice. Short-term effectiveness and safety results. Clin Exp Dermatol. 2023 (Apr 25). Doi: 10.1093/ced/llad153

Key clinical point: Tralokinumab demonstrated promising efficacy and an acceptable safety profile in a real-world cohort of patients with a long history of moderate-to-severe atopic dermatitis (AD) and multiple treatment failures.

Major finding: At week 16, the mean Eczema Area and Severity Index (EASI), SCORing AD, and peak pruritus numerical rating scale scores improved by 70.4%, 64.1%, and 57.1%, respectively (all P < .0001), and 57.6% of patients achieved a ≥75% improvement in EASI scores. The safety profile was acceptable.

Study details: Findings are from a multicenter retrospective study including 85 adult patients with moderate-to-severe AD who had unsuccessfully used prior therapy with systemics, biologics, or a Janus kinase inhibitor (n = 27) or were naive to advanced therapy (n = 58) and received tralokinumab.

Disclosures: This study did not receive any funding. Some authors declared serving as investigators, speakers, or consultants for or receiving lecture, speaking, or consulting fees from various sources.

Source: Pereyra-Rodriguez JJ et al. Treatment of severe atopic dermatitis with tralokinumab in real clinical practice. Short-term effectiveness and safety results. Clin Exp Dermatol. 2023 (Apr 25). Doi: 10.1093/ced/llad153

Key clinical point: Tralokinumab demonstrated promising efficacy and an acceptable safety profile in a real-world cohort of patients with a long history of moderate-to-severe atopic dermatitis (AD) and multiple treatment failures.

Major finding: At week 16, the mean Eczema Area and Severity Index (EASI), SCORing AD, and peak pruritus numerical rating scale scores improved by 70.4%, 64.1%, and 57.1%, respectively (all P < .0001), and 57.6% of patients achieved a ≥75% improvement in EASI scores. The safety profile was acceptable.

Study details: Findings are from a multicenter retrospective study including 85 adult patients with moderate-to-severe AD who had unsuccessfully used prior therapy with systemics, biologics, or a Janus kinase inhibitor (n = 27) or were naive to advanced therapy (n = 58) and received tralokinumab.

Disclosures: This study did not receive any funding. Some authors declared serving as investigators, speakers, or consultants for or receiving lecture, speaking, or consulting fees from various sources.

Source: Pereyra-Rodriguez JJ et al. Treatment of severe atopic dermatitis with tralokinumab in real clinical practice. Short-term effectiveness and safety results. Clin Exp Dermatol. 2023 (Apr 25). Doi: 10.1093/ced/llad153

Key clinical point: Compared with the usual emollient and cleanser skincare routine, an emollient plus balm combination significantly improved pruritus in patients with moderate-to-severe atopic dermatitis (AD) receiving systemic treatment.

Major finding: Patients treated with an emollient plus balm combination after pre-cleaning with a syndet (emollient “plus” group) vs the usual emollient and cleanser skincare routine (control group) had a significantly greater mean decrease in current pruritus after 70 days (P  =  .0277) and worse pruritus over the last 24 hours after 42 days (P  =  .025) of treatment.

Study details: This randomized controlled multicenter study included 57 adult patients with moderate-to-severe AD using systemic treatment who were randomly assigned 1:1 to the emollient “plus” group or the control group.

Disclosures: This study was funded by La Roche-Posay (LRP). Two authors declared being employees of LRP, and some authors declared serving on advisory boards or as speakers, consultants, or investigators in the presented trial or other clinical trials sponsored by various sources, including LRP.

Source: Magnolo N et al. Comparison of different skin care regimens in patients with moderate to severe atopic dermatitis receiving systemic treatment: A randomized controlled trial. J Eur Acad Dermatol Venereol. 2023 (Apr 24). Doi: 10.1111/jdv.18949

Key clinical point: Compared with the usual emollient and cleanser skincare routine, an emollient plus balm combination significantly improved pruritus in patients with moderate-to-severe atopic dermatitis (AD) receiving systemic treatment.

Major finding: Patients treated with an emollient plus balm combination after pre-cleaning with a syndet (emollient “plus” group) vs the usual emollient and cleanser skincare routine (control group) had a significantly greater mean decrease in current pruritus after 70 days (P  =  .0277) and worse pruritus over the last 24 hours after 42 days (P  =  .025) of treatment.

Study details: This randomized controlled multicenter study included 57 adult patients with moderate-to-severe AD using systemic treatment who were randomly assigned 1:1 to the emollient “plus” group or the control group.

Disclosures: This study was funded by La Roche-Posay (LRP). Two authors declared being employees of LRP, and some authors declared serving on advisory boards or as speakers, consultants, or investigators in the presented trial or other clinical trials sponsored by various sources, including LRP.

Source: Magnolo N et al. Comparison of different skin care regimens in patients with moderate to severe atopic dermatitis receiving systemic treatment: A randomized controlled trial. J Eur Acad Dermatol Venereol. 2023 (Apr 24). Doi: 10.1111/jdv.18949

Key clinical point: Compared with the usual emollient and cleanser skincare routine, an emollient plus balm combination significantly improved pruritus in patients with moderate-to-severe atopic dermatitis (AD) receiving systemic treatment.

Major finding: Patients treated with an emollient plus balm combination after pre-cleaning with a syndet (emollient “plus” group) vs the usual emollient and cleanser skincare routine (control group) had a significantly greater mean decrease in current pruritus after 70 days (P  =  .0277) and worse pruritus over the last 24 hours after 42 days (P  =  .025) of treatment.

Study details: This randomized controlled multicenter study included 57 adult patients with moderate-to-severe AD using systemic treatment who were randomly assigned 1:1 to the emollient “plus” group or the control group.

Disclosures: This study was funded by La Roche-Posay (LRP). Two authors declared being employees of LRP, and some authors declared serving on advisory boards or as speakers, consultants, or investigators in the presented trial or other clinical trials sponsored by various sources, including LRP.

Source: Magnolo N et al. Comparison of different skin care regimens in patients with moderate to severe atopic dermatitis receiving systemic treatment: A randomized controlled trial. J Eur Acad Dermatol Venereol. 2023 (Apr 24). Doi: 10.1111/jdv.18949

Key clinical point: Dupilumab is efficacious and safe in pediatric patients with uncontrolled atopic dermatitis (AD), including those aged 2 to <6 years.

Major finding: At week 16, the mean Eczema Area and Severity Index (EASI) score decreased significantly from 29.0 to 5.1 (P < .0001) and 73.3% and 53.3% of patients achieved ≥75% improvement in EASI and Scoring Atopic Dermatitis scores, respectively. The change in clinical scores was similar among the 2 to <6-year, 6 to <12-year, and 12 to <18-year subgroups. No serious treatment-emergent adverse events were observed.

Study details: This single-center real-world retrospective study included 39 patients aged 2 to <18 years with uncontrolled AD who received dupilumab therapy.

Disclosures: This study was supported by the National Natural Science Foundation of China. The authors declared no conflicts of interest.

Source: Wang Y et al. Dupilumab improves clinical scores in pediatric patients aged 2 to <18 years with uncontrolled atopic dermatitis: A single-center, real-world study. Dermatol Ther. 2023;5626410 (Apr 17). Doi: 10.1155/2023/5626410

Key clinical point: Dupilumab is efficacious and safe in pediatric patients with uncontrolled atopic dermatitis (AD), including those aged 2 to <6 years.

Major finding: At week 16, the mean Eczema Area and Severity Index (EASI) score decreased significantly from 29.0 to 5.1 (P < .0001) and 73.3% and 53.3% of patients achieved ≥75% improvement in EASI and Scoring Atopic Dermatitis scores, respectively. The change in clinical scores was similar among the 2 to <6-year, 6 to <12-year, and 12 to <18-year subgroups. No serious treatment-emergent adverse events were observed.

Study details: This single-center real-world retrospective study included 39 patients aged 2 to <18 years with uncontrolled AD who received dupilumab therapy.

Disclosures: This study was supported by the National Natural Science Foundation of China. The authors declared no conflicts of interest.

Source: Wang Y et al. Dupilumab improves clinical scores in pediatric patients aged 2 to <18 years with uncontrolled atopic dermatitis: A single-center, real-world study. Dermatol Ther. 2023;5626410 (Apr 17). Doi: 10.1155/2023/5626410

Key clinical point: Dupilumab is efficacious and safe in pediatric patients with uncontrolled atopic dermatitis (AD), including those aged 2 to <6 years.

Major finding: At week 16, the mean Eczema Area and Severity Index (EASI) score decreased significantly from 29.0 to 5.1 (P < .0001) and 73.3% and 53.3% of patients achieved ≥75% improvement in EASI and Scoring Atopic Dermatitis scores, respectively. The change in clinical scores was similar among the 2 to <6-year, 6 to <12-year, and 12 to <18-year subgroups. No serious treatment-emergent adverse events were observed.

Study details: This single-center real-world retrospective study included 39 patients aged 2 to <18 years with uncontrolled AD who received dupilumab therapy.

Disclosures: This study was supported by the National Natural Science Foundation of China. The authors declared no conflicts of interest.

Source: Wang Y et al. Dupilumab improves clinical scores in pediatric patients aged 2 to <18 years with uncontrolled atopic dermatitis: A single-center, real-world study. Dermatol Ther. 2023;5626410 (Apr 17). Doi: 10.1155/2023/5626410

Key Clinical Point: Crisaborole induces proteomic changes and modulates the lesional skin phenotype toward normal skin in mild-to-moderate atopic dermatitis (AD).

Major finding: At days 8 and 15, a markedly greater number of biomarkers were down-regulated with crisaborole vs vehicle (123 vs 9 and 162 vs 22, respectively), with a significantly higher rate of improvement in the overall lesional (45.9% vs 12.6% and 57.0% vs 28.3%, respectively; both P < .001) and nonlesional (53.0% vs 15.5% and 62.6% vs 36.8%, respectively; both P < .001) proteomes relative to a normal skin proteome.

Study details: This phase 2a study conducted a proteomic analysis in 20 control individuals and 40 adult patients with mild-to-moderate AD after double-blind, 1:1 random assignment of two target lesions in each patient with AD to crisaborole (2% ointment) or vehicle twice daily for 14 days.

Disclosures: This study was funded by Pfizer, New York. Some authors reported ties with various organizations, including Pfizer. One author declared being an employee of and holding shares in Pfizer.

Source: Kim M et al. Crisaborole reverses dysregulation of the mild to moderate atopic dermatitis proteome towards nonlesional and normal skin. J Am Acad Dermatol. 2023 (Apr 10). Doi: 10.1016/j.jaad.2023.02.064

Key Clinical Point: Crisaborole induces proteomic changes and modulates the lesional skin phenotype toward normal skin in mild-to-moderate atopic dermatitis (AD).

Major finding: At days 8 and 15, a markedly greater number of biomarkers were down-regulated with crisaborole vs vehicle (123 vs 9 and 162 vs 22, respectively), with a significantly higher rate of improvement in the overall lesional (45.9% vs 12.6% and 57.0% vs 28.3%, respectively; both P < .001) and nonlesional (53.0% vs 15.5% and 62.6% vs 36.8%, respectively; both P < .001) proteomes relative to a normal skin proteome.

Study details: This phase 2a study conducted a proteomic analysis in 20 control individuals and 40 adult patients with mild-to-moderate AD after double-blind, 1:1 random assignment of two target lesions in each patient with AD to crisaborole (2% ointment) or vehicle twice daily for 14 days.

Disclosures: This study was funded by Pfizer, New York. Some authors reported ties with various organizations, including Pfizer. One author declared being an employee of and holding shares in Pfizer.

Source: Kim M et al. Crisaborole reverses dysregulation of the mild to moderate atopic dermatitis proteome towards nonlesional and normal skin. J Am Acad Dermatol. 2023 (Apr 10). Doi: 10.1016/j.jaad.2023.02.064

Key Clinical Point: Crisaborole induces proteomic changes and modulates the lesional skin phenotype toward normal skin in mild-to-moderate atopic dermatitis (AD).

Major finding: At days 8 and 15, a markedly greater number of biomarkers were down-regulated with crisaborole vs vehicle (123 vs 9 and 162 vs 22, respectively), with a significantly higher rate of improvement in the overall lesional (45.9% vs 12.6% and 57.0% vs 28.3%, respectively; both P < .001) and nonlesional (53.0% vs 15.5% and 62.6% vs 36.8%, respectively; both P < .001) proteomes relative to a normal skin proteome.

Study details: This phase 2a study conducted a proteomic analysis in 20 control individuals and 40 adult patients with mild-to-moderate AD after double-blind, 1:1 random assignment of two target lesions in each patient with AD to crisaborole (2% ointment) or vehicle twice daily for 14 days.

Disclosures: This study was funded by Pfizer, New York. Some authors reported ties with various organizations, including Pfizer. One author declared being an employee of and holding shares in Pfizer.

Source: Kim M et al. Crisaborole reverses dysregulation of the mild to moderate atopic dermatitis proteome towards nonlesional and normal skin. J Am Acad Dermatol. 2023 (Apr 10). Doi: 10.1016/j.jaad.2023.02.064

Key clinical point: Tralokinumab-mediated specific targeting of interleukin-13 is effective and safe in treating adolescents with moderate-to-severe atopic dermatitis (AD).

Major finding: At week 16, a significantly higher proportion of patients receiving 150 mg or 300 mg tralokinumab vs placebo achieved an Investigator’s Global Assessment score of 0 or 1 (21.4% and 17.5% vs 4.3%; P < .001 and P  =  .002, respectively) and ≥75% improvement in the Eczema Area and Severity Index score (28.6% and 27.8% vs 6.4%, respectively; both P < .001) without rescue medication. Most adverse events were mild or moderate in severity.

Study details: Findings are from the phase 3 ECZTRA 6 trial including 289 adolescents (12-17 years) with moderate-to-severe AD who were randomly assigned to receive 150 mg tralokinumab (n = 98), 300 mg tralokinumab (n = 97), or placebo (n = 94).

Disclosures: This study was funded by LEO Pharma. Some authors reported ties with various organizations including LEO Pharma. Five authors declared being employees of or holding shares in LEO Pharma.

Source: Paller AS et al. Efficacy and safety of tralokinumab in adolescents with moderate to severe atopic dermatitis: The phase 3 ECZTRA 6 randomized clinical trial. JAMA Dermatol. 2023 (Apr 19). Doi: 10.1001/jamadermatol.2023.0627

Key clinical point: Tralokinumab-mediated specific targeting of interleukin-13 is effective and safe in treating adolescents with moderate-to-severe atopic dermatitis (AD).

Major finding: At week 16, a significantly higher proportion of patients receiving 150 mg or 300 mg tralokinumab vs placebo achieved an Investigator’s Global Assessment score of 0 or 1 (21.4% and 17.5% vs 4.3%; P < .001 and P  =  .002, respectively) and ≥75% improvement in the Eczema Area and Severity Index score (28.6% and 27.8% vs 6.4%, respectively; both P < .001) without rescue medication. Most adverse events were mild or moderate in severity.

Study details: Findings are from the phase 3 ECZTRA 6 trial including 289 adolescents (12-17 years) with moderate-to-severe AD who were randomly assigned to receive 150 mg tralokinumab (n = 98), 300 mg tralokinumab (n = 97), or placebo (n = 94).

Disclosures: This study was funded by LEO Pharma. Some authors reported ties with various organizations including LEO Pharma. Five authors declared being employees of or holding shares in LEO Pharma.

Source: Paller AS et al. Efficacy and safety of tralokinumab in adolescents with moderate to severe atopic dermatitis: The phase 3 ECZTRA 6 randomized clinical trial. JAMA Dermatol. 2023 (Apr 19). Doi: 10.1001/jamadermatol.2023.0627

Key clinical point: Tralokinumab-mediated specific targeting of interleukin-13 is effective and safe in treating adolescents with moderate-to-severe atopic dermatitis (AD).

Major finding: At week 16, a significantly higher proportion of patients receiving 150 mg or 300 mg tralokinumab vs placebo achieved an Investigator’s Global Assessment score of 0 or 1 (21.4% and 17.5% vs 4.3%; P < .001 and P  =  .002, respectively) and ≥75% improvement in the Eczema Area and Severity Index score (28.6% and 27.8% vs 6.4%, respectively; both P < .001) without rescue medication. Most adverse events were mild or moderate in severity.

Study details: Findings are from the phase 3 ECZTRA 6 trial including 289 adolescents (12-17 years) with moderate-to-severe AD who were randomly assigned to receive 150 mg tralokinumab (n = 98), 300 mg tralokinumab (n = 97), or placebo (n = 94).

Disclosures: This study was funded by LEO Pharma. Some authors reported ties with various organizations including LEO Pharma. Five authors declared being employees of or holding shares in LEO Pharma.

Source: Paller AS et al. Efficacy and safety of tralokinumab in adolescents with moderate to severe atopic dermatitis: The phase 3 ECZTRA 6 randomized clinical trial. JAMA Dermatol. 2023 (Apr 19). Doi: 10.1001/jamadermatol.2023.0627

Key clinical point: Upadacitinib is as effective and safe in adolescents with moderate-to-severe atopic dermatitis (AD) as in adults with AD.

Major finding: At week 16, in Measure Up 1 and 2 and AD Up, a significantly higher proportion of patients receiving 15/30 mg upadacitinib vs placebo achieved Eczema Area and Severity Index-75 (73%/78%, 69%/73%, and 63%/84% vs 12%, 13%, and 30%, respectively; all P < .001) and Investigator’s Global Assessment score of 0/1 (45%/64%, 45%/59%, and 38%/67% vs 7%, 5%, and 11%, respectively; all P < .001). The safety profile was consistent in adolescents and adults.

Study details: This interim analysis of 3 phase 3 trials included 552 adolescents (12-17 years) with moderate-to-severe AD who were randomly assigned to receive 15 mg upadacitinib, 30 mg upadacitinib, or placebo alone (Measure Up 1 and Measure Up 2) or with topical corticosteroids (AD Up).

Disclosures: This study was funded by AbbVie Inc. Some authors reported ties with various organizations, including AbbVie. Nine authors declared being employees of or holding stock or stock options in AbbVie.

Source: Paller AS et al. Efficacy and safety of upadacitinib treatment in adolescents with moderate-to-severe atopic dermatitis: Analysis of the Measure Up 1, Measure Up 2, and AD Up randomized clinical trials. JAMA Dermatol. 2023 (Apr 12). Doi: 10.1001/jamadermatol.2023.0391

Key clinical point: Upadacitinib is as effective and safe in adolescents with moderate-to-severe atopic dermatitis (AD) as in adults with AD.

Major finding: At week 16, in Measure Up 1 and 2 and AD Up, a significantly higher proportion of patients receiving 15/30 mg upadacitinib vs placebo achieved Eczema Area and Severity Index-75 (73%/78%, 69%/73%, and 63%/84% vs 12%, 13%, and 30%, respectively; all P < .001) and Investigator’s Global Assessment score of 0/1 (45%/64%, 45%/59%, and 38%/67% vs 7%, 5%, and 11%, respectively; all P < .001). The safety profile was consistent in adolescents and adults.

Study details: This interim analysis of 3 phase 3 trials included 552 adolescents (12-17 years) with moderate-to-severe AD who were randomly assigned to receive 15 mg upadacitinib, 30 mg upadacitinib, or placebo alone (Measure Up 1 and Measure Up 2) or with topical corticosteroids (AD Up).

Disclosures: This study was funded by AbbVie Inc. Some authors reported ties with various organizations, including AbbVie. Nine authors declared being employees of or holding stock or stock options in AbbVie.

Source: Paller AS et al. Efficacy and safety of upadacitinib treatment in adolescents with moderate-to-severe atopic dermatitis: Analysis of the Measure Up 1, Measure Up 2, and AD Up randomized clinical trials. JAMA Dermatol. 2023 (Apr 12). Doi: 10.1001/jamadermatol.2023.0391

Key clinical point: Upadacitinib is as effective and safe in adolescents with moderate-to-severe atopic dermatitis (AD) as in adults with AD.

Major finding: At week 16, in Measure Up 1 and 2 and AD Up, a significantly higher proportion of patients receiving 15/30 mg upadacitinib vs placebo achieved Eczema Area and Severity Index-75 (73%/78%, 69%/73%, and 63%/84% vs 12%, 13%, and 30%, respectively; all P < .001) and Investigator’s Global Assessment score of 0/1 (45%/64%, 45%/59%, and 38%/67% vs 7%, 5%, and 11%, respectively; all P < .001). The safety profile was consistent in adolescents and adults.

Study details: This interim analysis of 3 phase 3 trials included 552 adolescents (12-17 years) with moderate-to-severe AD who were randomly assigned to receive 15 mg upadacitinib, 30 mg upadacitinib, or placebo alone (Measure Up 1 and Measure Up 2) or with topical corticosteroids (AD Up).

Disclosures: This study was funded by AbbVie Inc. Some authors reported ties with various organizations, including AbbVie. Nine authors declared being employees of or holding stock or stock options in AbbVie.

Source: Paller AS et al. Efficacy and safety of upadacitinib treatment in adolescents with moderate-to-severe atopic dermatitis: Analysis of the Measure Up 1, Measure Up 2, and AD Up randomized clinical trials. JAMA Dermatol. 2023 (Apr 12). Doi: 10.1001/jamadermatol.2023.0391